Clinical trial · no report yet · Phase 3
NCT03833167
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
- NCT03833167 ↗
- Terminated
- Merck Sharp & Dohme LLC
- 22 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 9 | |
| Podcasts | 8 | |
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- Pembrolizumab; Placebo
- Arms
- Pembrolizumab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 450
- Primary outcomes
- Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Apr 1, 2019
- Primary completion
- Jun 28, 2024
- Results posted
- Yes
- Registry record
- NCT03833167 · updated Sep 28, 2026